Legal status in Australia. Psilocybin is listed as a Schedule 9 (Prohibited Substance) under the Poisons Standard (the current SUSMP), meaning its manufacture, possession, supply, and use outside of strictly authorised circumstances is a criminal offence under state and territory law. From 1 July 2023, the Therapeutic Goods Administration (TGA) created a narrow Schedule 8 pathway: registered psychiatrists who hold Authorised Prescriber status may prescribe psilocybin , in combination with psychological support , for treatment-resistant depression only. Access outside this framework, including importation or personal possession without a valid authorisation, remains prohibited and carries serious criminal penalties.
Chemistry and pharmacology. Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine; molecular formula C12H17N2O4P) is a prodrug rapidly dephosphorylated in the body to psilocin, which binds with high affinity at serotonin 5-HT2A receptors in the cortex. This receptor activity is understood to underlie the characteristic perceptual, cognitive, and affective changes associated with the compound. Psilocybin is found across numerous fungal species, most prominently within the genera Psilocybe and Panaeolus, and has no approved therapeutic good currently on the Australian Register of Therapeutic Goods (ARTG) for retail supply.
Research context. Since approximately 2010, a body of peer-reviewed clinical research , including trials at Johns Hopkins University and Imperial College London; has examined psilocybin in controlled, supervised settings. Quantities used in these studies are reported in the published literature as research protocols and were administered under ethics approval with trained clinical oversight; they do not constitute prescribing guidance and cannot be replicated legally outside an authorised clinical framework in Australia. Study designs, endpoints, and limitations vary considerably, and regulatory bodies including the TGA note that the overall evidence base remains early-stage.
Safety and risk profile. Psilocybin is not considered physically addictive in classical pharmacological terms, but it is not without risk. Documented adverse effects in research and case literature include acute anxiety, paranoia, and psychosis-like episodes, particularly in individuals with a personal or family history of psychotic disorders. The Australian Drug Foundation (ADF) notes that set (mindset) and setting substantially influence acute response, and that combining psilocybin with other substances carries unpredictable risks. Outside a supervised clinical environment, there is no quality control over fungal material, no medical oversight, and no legal protection, factors that materially increase the risk of harm.
Sources: